Gilead Sciences (NASDAQ:GILD) Shares Acquired Rep. Carol D. Miller

Representative Carol D. Miller (R-West Virginia) recently bought shares of Gilead Sciences, Inc. (NASDAQ:GILD). In a filing disclosed on April 11th, the Representative disclosed that they had bought between $1,001 and $15,000 in Gilead Sciences stock on March 10th. The trade occurred in the Representative’s “MATT MILLER INVESTMENT MANAGEMENT ACCOUNT” account.

Representative Carol D. Miller also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of Aflac (NYSE:AFL) on 3/10/2025.
• Purchased $1,001 – $15,000 in shares of Hershey (NYSE:HSY) on 3/10/2025.
• Sold $1,001 – $15,000 in shares of Pfizer (NYSE:PFE) on 3/10/2025.
• Purchased $1,001 – $15,000 in shares of Lockheed Martin (NYSE:LMT) on 3/10/2025.
• Purchased $1,001 – $15,000 in shares of PepsiCo (NASDAQ:PEP) on 3/10/2025.
• Purchased $1,001 – $15,000 in shares of Honeywell International (NASDAQ:HON) on 3/10/2025.
• Sold $1,001 – $15,000 in shares of U.S. Bancorp (NYSE:USB) on 3/10/2025.
• Purchased $1,001 – $15,000 in shares of CME Group (NASDAQ:CME) on 3/10/2025.
• Sold $1,001 – $15,000 in shares of Target (NYSE:TGT) on 3/10/2025.
• Purchased $1,001 – $15,000 in shares of American Water Works (NYSE:AWK) on 3/10/2025.

Gilead Sciences Stock Performance

GILD stock traded up $0.20 during midday trading on Wednesday, reaching $105.88. The company had a trading volume of 869,148 shares, compared to its average volume of 8,873,731. The firm has a market capitalization of $131.84 billion, a PE ratio of 286.16, a P/E/G ratio of 0.71 and a beta of 0.32. Gilead Sciences, Inc. has a fifty-two week low of $62.07 and a fifty-two week high of $119.96. The company has a quick ratio of 1.20, a current ratio of 1.50 and a debt-to-equity ratio of 1.24. The stock has a 50 day moving average price of $108.63 and a 200 day moving average price of $97.11.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 EPS for the quarter, topping the consensus estimate of $1.67 by $0.23. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. Analysts anticipate that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, March 28th. Investors of record on Friday, March 14th were paid a $0.79 dividend. This represents a $3.16 dividend on an annualized basis and a yield of 2.98%. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.77. The ex-dividend date of this dividend was Friday, March 14th. Gilead Sciences’s dividend payout ratio (DPR) is 854.05%.

Insider Activity at Gilead Sciences

In other news, CFO Andrew D. Dickinson sold 142,180 shares of Gilead Sciences stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $97.22, for a total value of $13,822,739.60. Following the sale, the chief financial officer now directly owns 129,873 shares in the company, valued at $12,626,253.06. This trade represents a 52.26 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In the last quarter, insiders have sold 300,285 shares of company stock valued at $30,274,875. 0.16% of the stock is owned by insiders.

Institutional Investors Weigh In On Gilead Sciences

Hedge funds have recently bought and sold shares of the company. HHM Wealth Advisors LLC increased its holdings in shares of Gilead Sciences by 118.5% in the fourth quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 154 shares in the last quarter. YANKCOM Partnership bought a new position in Gilead Sciences during the 4th quarter worth about $28,000. Decker Retirement Planning Inc. bought a new stake in shares of Gilead Sciences in the fourth quarter valued at about $29,000. Crews Bank & Trust acquired a new position in shares of Gilead Sciences during the fourth quarter worth about $31,000. Finally, Stephens Consulting LLC grew its holdings in shares of Gilead Sciences by 325.0% during the fourth quarter. Stephens Consulting LLC now owns 340 shares of the biopharmaceutical company’s stock worth $31,000 after buying an additional 260 shares in the last quarter. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on GILD shares. DZ Bank raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $108.00 price target for the company in a report on Thursday, February 13th. Piper Sandler lifted their price target on shares of Gilead Sciences from $105.00 to $110.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 12th. Oppenheimer raised their price objective on Gilead Sciences from $115.00 to $132.00 and gave the stock an “outperform” rating in a research note on Tuesday, March 4th. Deutsche Bank Aktiengesellschaft raised Gilead Sciences from a “hold” rating to a “buy” rating and boosted their target price for the stock from $80.00 to $120.00 in a research report on Tuesday, February 18th. Finally, Morgan Stanley increased their price target on Gilead Sciences from $123.00 to $130.00 and gave the company an “overweight” rating in a research report on Tuesday, March 11th. Eleven investment analysts have rated the stock with a hold rating, fifteen have given a buy rating and four have issued a strong buy rating to the company’s stock. According to MarketBeat, Gilead Sciences presently has an average rating of “Moderate Buy” and an average price target of $105.12.

About Representative Miller

Carol Miller (Republican Party) is a member of the U.S. House, representing West Virginia’s 1st Congressional District. She assumed office on January 3, 2023. Her current term ends on January 3, 2027.

Miller (Republican Party) ran for re-election to the U.S. House to represent West Virginia’s 1st Congressional District. She won in the general election on November 5, 2024.

West Virginia’s 3rd Congressional District race was identified as a 2018 battleground that might have affected partisan control of the U.S. House in the 116th Congress. Incumbent Evan Jenkins (R) did not seek re-election in 2018, leaving the seat open. In the campaign, Miller emphasized her endorsement by President Donald Trump (R). Lara Trump, Senior Advisor to Donald J. Trump for President, Inc., said, “Carol is pro-coal, pro-Second Amendment, and pro-Trump through and through, and is prepared to tackle the opioid epidemic that’s affected countless West Virginians.” Miller also supported the construction of a wall on the southern U.S. border and the Tax Cuts and Jobs Act (TCJA).

Miller is a former Republican member of the West Virginia House of Delegates, representing District 16 from 2006 to 2018.

Miller has also worked in real estate and owns a bison farm.

Carol Miller was born in Columbus, Ohio. Miller graduated from Bexley High School in 1968. She earned a B.S. from Columbia College in 1972. Her career experience includes owning and operating Swann Ridge Bison Farm and working as a real estate manager.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.